[1]
Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol., 2010, 11(5), 373-384.
[2]
Liu, Y.; Yin, H.; Zhao, M.; Lu, Q. TLR2 and TLR4 in autoimmune diseases: A comprehensive review. Clin. Rev. Allergy Immunol., 2014, 47(2), 136-147.
[3]
Maglione, P.J.; Simchoni, N.; Cunningham-Rundles, C. Toll-like receptor signaling in primary immune deficiencies. Ann. N. Y. Acad. Sci., 2015.
[4]
Uehara, A.; Fujimoto, Y.; Fukase, K.; Takada, H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol. Immunol., 2007, 44(12), 3100-3111.
[5]
Pegu, A.; Qin, S.; Fallert Junecko, B.A.; Nisato, R.E.; Pepper, M.S.; Reinhart, T.A. Human lymphatic endothelial cells express multiple functional TLRs. J. Immunol., 2008, 180(5), 3399-3405.
[6]
Schenten, D.; Medzhitov, R. The control of adaptive immune responses by the innate immune system. Adv. Immunol., 2011, 109, 87-124.
[7]
Gao, W.; Xiong, Y.; Li, Q.; Yang, H. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. Front. Physiol., 2017, 8, 508.
[8]
Prattichizzo, F.; De Nigris, V.; Spiga, R.; Mancuso, E.; La Sala, L.; Antonicelli, R.; Testa, R.; Procopio, A.D.; Olivieri, F.; Ceriello, A. Inflammageing and metaflammation: The yin and yang of type 2 diabetes. Ageing Res. Rev., 2018, 41, 1-17.
[9]
Lee, K.Y.; Mooney, D.J. Alginate: properties and biomedical applications. Prog. Polym. Sci., 2012, 37(1), 106-126.
[10]
Mirshafiey, A.; Matsuo, H.; Nakane, S.; Rehm, B.H.; Koh, C.S.; Miyoshi, S. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacol. Immunotoxicol., 2005, 27(2), 255-265.
[11]
Fattahi, M.J.; Abdollahi, M.; Agha Mohammadi, A.; Rastkari, N.; Khorasani, R.; Ahmadi, H.; Tofighi Zavareh, F.; Sedaghat, R.; Tabrizian, N.; Mirshafiey, A. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol. Immunotoxicol., 2015, 37(6), 535-540.
[12]
Barati, A.; Jamshidi, A.R.; Ahmadi, H.; Aghazadeh, Z.; Mirshafiey, A. Effects of beta-d-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, RORgammat, IL4 and GATA3 gene expressions in rheumatoid arthritis patients. Drug Des. Devel. Ther., 2017, 11, 1027-1033.
[13]
Jahromi, S.S.; Jamshidi, M.M.; Farazmand, A.; Aghazadeh, Z.; Yousefi, M.; Mirshafiey, A. Pharmacological effects of beta-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-kappaB gene expression, as target molecules in inflammatory reactions. Pharmacol. Rep., 2017, 69(3), 479-484.
[14]
Radstake, T.R.; Roelofs, M.F.; Jenniskens, Y.M.; Oppers-Walgreen, B.; van Riel, P.L.; Barrera, P.; Joosten, L.A.; van den Berg, W.B. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum., 2004, 50(12), 3856-3865.
[15]
Kowalski, M.L.; Wolska, A.; Grzegorczyk, J.; Hilt, J.; Jarzebska, M.; Drobniewski, M.; Synder, M.; Kurowski, M. Increased responsiveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis. Mediators Inflamm., 2008, 2008, 132732.
[16]
Kirchner, M.; Sonnenschein, A.; Schoofs, S.; Schmidtke, P.; Umlauf, V.N.; Mannhardt-Laakmann, W. Surface expression and genotypes of Toll-like receptors 2 and 4 in patients with juvenile idiopathic arthritis and systemic lupus erythematosus. Pediatr. Rheumatol. Online J., 2013, 11(1), 9.
[17]
Kwok, S.K.; Cho, M.L.; Her, Y.M.; Oh, H.J.; Park, M.K.; Lee, S.Y.; Woo, Y.J.; Ju, J.H.; Park, K.S.; Kim, H.Y.; Park, S.H. TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren’s syndrome. Arthritis Res. Ther., 2012, 14(2), R64.
[18]
Carrasco, S.; Neves, F.S.; Fonseca, M.H.; Goncalves, C.R.; Saad, C.G.; Sampaio-Barros, P.D.; Goldenstein-Schainberg, C. Toll-like receptor (TLR) 2 is upregulated on peripheral blood monocytes of patients with psoriatic arthritis: A role for a gram-positive inflammatory trigger? Clin. Exp. Rheumatol., 2011, 29(6), 958-962.
[19]
Garcia-Rodriguez, S.; Arias-Santiago, S.; Perandres-Lopez, R.; Castellote, L.; Zumaquero, E.; Navarro, P.; Buendia-Eisman, A.; Ruiz, J.C.; Orgaz-Molina, J.; Sancho, J.; Zubiaur, M. Increased gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol., 2013, 27(2), 242-250.
[20]
Andersson, A.; Covacu, R.; Sunnemark, D.; Danilov, A.I.; Dal Bianco, A.; Khademi, M.; Wallstrom, E.; Lobell, A.; Brundin, L.; Lassmann, H.; Harris, R.A. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J. Leukoc. Biol., 2008, 84(5), 1248-1255.
[21]
De Jager, P.L.; Franchimont, D.; Waliszewska, A.; Bitton, A.; Cohen, A.; Langelier, D.; Belaiche, J.; Vermeire, S.; Farwell, L.; Goris, A.; Libioulle, C.; Jani, N.; Dassopoulos, T.; Bromfield, G.P.; Dubois, B.; Cho, J.H.; Brant, S.R.; Duerr, R.H.; Yang, H.; Rotter, J.I.; Silverberg, M.S.; Steinhart, A.H.; Daly, M.J.; Podolsky, D.K.; Louis, E.; Hafler, D.A.; Rioux, J.D.; Quebec, I.B.D.G.C.; Consortium, N.I.G. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun., 2007, 8(5), 387-397.
[22]
Menon, M.B.; Gaestel, M. TPL2 meets p38MAPK: Emergence of a novel positive feedback loop in inflammation. Biochem. J., 2016, 473(19), 2995-2999.
[23]
Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol., 2004, 4(7), 499-511.
[24]
Didierlaurent, A.; Brissoni, B.; Velin, D.; Aebi, N.; Tardivel, A.; Kaslin, E.; Sirard, J.C.; Angelov, G.; Tschopp, J.; Burns, K. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell. Biol., 2006, 26(3), 735-742.
[25]
Bourgeois-Daigneault, M.C.; Pezeshki, A.M.; Galbas, T.; Houde, M.; Baril, M.; Fruh, K.; Amrani, A.; Ishido, S.; Lamarre, D.; Thibodeau, J. Tollip-induced down-regulation of MARCH1. Results Immunol., 2013, 3, 17-25.
[26]
Sharifi, L.; Aghamohammadi, A.; Mohsenzadegan, M.; Rezaei, N.; Towfighi Zavareh, F.; Moshiri, M.; Bokaie, S.; Barati, A.; Sayedi, S.J.; Azizi, G.; Mirshafiey, A. Immunomodulation of TLR2 and TLR4 by G2013 (alfa-L-Guluronic acid) in CVID Patients. Int. J. Pediatr., 2017, 5(7), 5327-5337.
[27]
Sharifi, L.; Aghamohammadi, A.; Rezaei, N.; Yazdani, R.; Mahmoudi, M.; Amiri, M.M.; Masoumi, F.; Bokaie, S.; Tavasolian, P.; Sanaei, R.; Moshiri, M.; Tavakolinia, N.; Alinia, T.; Azizi, G.; Mirshafiey, A. The Profile of Toll-like Receptor 2 (TLR2), TLR4 and Their Cytosolic Downstream Signaling Pathway in Common Variable Immunodeficiency (CVID) Patients. Iran. J. Allergy Asthma Immunol., 2018, 17(2), 188-200.
[28]
Netea, M.G.; van der Graaf, C.; Van der Meer, J.W.; Kullberg, B.J. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J. Leukoc. Biol., 2004, 75(5), 749-755.
[29]
Afraei, S.; Azizi, G.; Zargar, S.J.; Sedaghat, R.; Mirshafiey, A. New therapeutic approach by G2013 in experimental model of multiple sclerosis. Acta Neurol. Belg., 2015, 115(3), 259-266.
[30]
Mirshafiey, A.; Hosseini, S.; Afraei, S.; Rastkari, N.; Zavareh, F.T.; Azizi, G. Anti-aging property of G2013 molecule as a novel immunosuppressive agent on enzymatic and non-enzymatic oxidative stress determinants in Rat model. Curr. Drug Discov. Technol., 2016, 13(1), 25-33.
[31]
Nazeri, S.; Khadem Azarian, S.; Fattahi, M.J.; Sedaghat, R.; Tofighi Zavareh, F.; Aghazadeh, Z.; Abdollahi, M.; Mirshafiey, A. Preclinical and pharmacotoxicology evaluation of alpha-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property. Immunopharmacol. Immunotoxicol., 2017, 39(2), 59-65.
[32]
Arjomand Fard, N.; Tabrizian, N.; Mirzaei, R.; Hadjati, J.; Tofighi Zavareh, F.; Salehi Nodeh, A.R.; Mirshafiey, A. Efficacy and safety of g2013 as a novel immunosuppressive agent on differentiation, maturation and function of human dendritic cells. Iran. J. Public Health, 2017, 46(2), 216-221.
26
1